The Biden administration on Tuesday unveiled the first 10 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off a controversial process that aims to make costly medications more affordable for older Americans.

President Joe Biden’s Inflation Reduction Act, which passed in a party-line vote last year, gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly 60-year history. The agreed-upon prices for the first round of drugs are scheduled to go into effect in 2026.

  • MicroWave@lemmy.worldOP
    link
    fedilink
    English
    arrow-up
    41
    ·
    1 year ago

    Here are the 10 drugs subject to the initial talks this year:

    • Eliquis, made by Bristol-Myers Squibb, is used to prevent blood clotting to reduce the risk of stroke.
    • Jardiance, made by Boehringer Ingelheim, is used to lower blood sugar for people with type 2 diabetes.
    • Xarelto, made by Johnson & Johnson, is used to prevent blood clotting to reduce the risk of stroke.
    • Januvia, made by Merck, is used to lower blood sugar for people with type 2 diabetes.
    • Farxiga, made by AstraZeneca, is used to treat type 2 diabetes.
    • Entresto, made by Novartis, is used to treat certain types of heart failure.
    • Enbrel, made by Amgen, is used to treat rheumatoid arthritis.
    • Imbruvica, made by AbbVie, is used to treat different types of blood cancers.
    • Stelara, made by Janssen, is used to treat Crohn’s disease.
    • Fiasp and NovoLog, insulins made by Novo Nordisk.
    • bioemerl@kbin.social
      link
      fedilink
      arrow-up
      13
      ·
      1 year ago

      The most curious thing here is that they’re all from different companies. I think this is a big trial run.

      • MicroWave@lemmy.worldOP
        link
        fedilink
        English
        arrow-up
        13
        ·
        1 year ago

        I think you’re right:

        “I think it’s incredibly important to keep in mind that the negotiation process is cumulative,” said Leigh Purvis, a prescription drug policy principal with AARP Public Policy Institute. “We could have as many as 60 drugs negotiated by 2029.